A Phase 4 interventional study of Nanodropper and Proparacaine HCl 0.5% and Standard Eye Drop Bottle with Proparacaine HCl 0.5% in Corneal Diseases and Effectiveness of Microdrops, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Columbia University · Phase 4, Interventional, and Device feasibility
The goal of this clinical trial is to compare the onset and duration of numbness of the surface of the eye following the administration of numbing drops, called proparacaine, using either a standard eye drop bottle or a "Nanodropper" adaptor. The Nanodropper is designed to administer smaller-sized drops, or microdrops.
Participants will:
This study could help us find a way to use less medication while still effectively administering eye medications, potentially saving money and reducing medical waste.
130 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.
This study's enrollment of 56 is above the median of 32 across 78 interventional studies indexed under Corneal Diseases.
Browse Corneal Diseases studies →Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.
Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eyes randomized to this arm will receive a standard drop of 0.5% proparacaine HCl
Combination Product: Standard Eye Drop Bottle with Proparacaine HCl 0.5%
Eyes randomized to this arm will receive a Nanodropper-mediated microdrop of 0.5% proparacaine HCl
Combination Product: Nanodropper and Proparacaine HCl 0.5%
The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
Corneal Anesthesia
The primary outcome is the percent or proportion of subjects that achieve anesthesia at the 5-minute time point
Time frame: 5 minutes
Plan to share: No
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Columbia University